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Terminology of carbapenem resistance 14 
 15 
40-Word summary 16 
The term ‘CRE’ has become inadequate with the advent of new therapies.  These make it essential for 17 
authors and licensing agencies to specify the particular carbapenemase(s) meant.  The future may 18 




  23 
Abstract.  Carbapenem resistance in Gram-negative bacteria is a public health concern.  Numerous 24 
government and agency reports consequently discuss ‘CRE’ and ‘CROs’, meaning ‘Carbapenem-25 
Resistant Enterobacterales’ or ‘Carbapenem-resistant organisms’.  Unfortunately these terms are 26 
fuzzy.  Do they include (i) Proteeae with inherent imipenem resistance, (ii) porin-deficient 27 
Enterobacterales resistant to ertapenem but not other carbapenems, (iii) Enterobacterales with OXA-28 
48-like enzymes that remain ‘carbapenem susceptible’ at breakpoint, and (iv) Pseudomonas 29 
aeruginosa that merely lack OprD? Counting carbapenemase-producing Enterobacterales/organisms 30 
(‘CPE’ or ‘CPOs’) is better but still insufficient, because different carbapenemases have differing 31 
treatment implications, particularly for new b-lactam/b-lactamase inhibitor combinations.   At the 32 
least it is essential for authors, journals, and regulatory agencies to specify the carbapenemases 33 
meant.  The future may demand even greater precision, for mutations can alter activity, and the ability 34 





  40 
For 25 years after imipenem’s launch in 1985, carbapenems were the ‘go to’ antibiotics for infections 41 
involving multiresistant Gram-negative bacteria. The recent accumulation of carbapenem resistance 42 
among Enterobacterales consequently is concerning, and these organisms top the WHO’s priority list 43 
of resistant pathogens, along with ‘carbapenem-resistant Acinetobacter baumannii’ and 44 
‘carbapenem-resistant ‘Pseudomonas aeruginosa’[1]   Carbapenem-resistant Enterobacterales also 45 
achieve the top tier of the CDC’s ‘Urgent Resistance Threats’ [2] and are prioritised in the UK’s 5-Year 46 
antimicrobial resistance national action plan [3]. 47 
 48 
‘Carbapenem-resistant’: What is included? 49 
If we are to prioritise carbapenem resistance we need a clear definition. Unfortunately the moniker is 50 
elastic, meaning that prevalence rates of ‘carbapenem resistance’ can be misleading.  51 
 It is easy to miss this lack of clarity, especially once ‘Carbapenem-Resistant Enterobacterales’ 52 
and ‘Carbapenem-Resistant Organisms’ are shortened to acronyms – CREs and CROs.  In reality, these 53 
encompass multiple species and mechanisms, differing greatly in significance.  This is unlike, say, 54 
‘MRSA’, which denotes a single species almost always with one mechanism, or even ‘ESBL producers’ 55 
where – although ESBLs belong to multiple families – they almost all are Class A b-lactamases attacking 56 
oxyimino-aminothiazolyl cephalosporins, not cephamycins nor carbapenems, and inhibited by 57 
clavulanate and penicillanic acid sulfones [4]. 58 
Examples illustrate the problem.  First, consider a Proteus mirabilis, Morganella morganii or 59 
Providencia spp. with an imipenem MIC of 8 mg/L.  Is this a ‘CRE’, despite meropenem and ertapenem, 60 
of (say) MICs 0.03 mg/L?  Imipenem MIC90s of 8 mg/L were reported for Proteeae when imipenem 61 
was launched [5], but there is no evidence that such Proteeae have since proliferated, or are a source 62 
of failures with imipenem.  Secondly, what about a Klebsiella or Enterobacter spp. with (resistant) 63 
ertapenem MICs of 2 or 4 mg/L but retained – albeit reduced – susceptibility to imipenem and 64 
meropenem (MICs, 0.25-0.5 mg/L)?  This profile commonly arises via combinations of AmpC or ESBL 65 
activity together with porin loss [6].  Does resistance to ertapenem qualify the isolate as a ‘CRE’?    On 66 
the other hand, how about a Klebsiella with weakly-expressed OXA-48 enzyme, susceptible to all 67 
carbapenems at clinical breakpoints, but meeting EUCAST’s ‘screening threshold’ of a meropenem 68 
MIC >0.12 mg/L? It fails the literal definition of ‘CRE’ but has a carbapenemase.  Lastly, most 69 
‘carbapenem-resistant Pseudomonas aeruginosa’ have simply lost OprD and this, of itself, 70 
compromises only carbapenems.  Such isolates are ‘CROs’, but present little problem unless they have 71 
other resistances. In the UK twice as many P. aeruginosa are ‘CROs’ as are ceftazidime resistant [7]. 72 
These points are more than pedantic.   A rate of 20% carbapenem resistance in P. aeruginosa 73 
is undesirable, but not catastrophic if most are OprD mutants. The situation is more troubling if 40% 74 
of carbapenem-resistant P. aeruginosa have carbapenemases, as in parts of the Middle East [8].  The 75 
WHO’s generic inclusion of ‘carbapenem-resistant P. aeruginosa’ among its priorities is unhelpful.   76 
And, whilst ertapenem-resistant Enterobacterales with ESBLs and impermeability cause problems in 77 
individual patients, and can be selected during carbapenem therapy, their resistance is often unstable, 78 
limiting impact. They rarely cause outbreaks.  OXA-48-like enzymes, by contrast, are plasmid-79 
mediated, allowing horizontal transfer; moreover, producers with low MICs are easily overlooked, 80 
permitting ‘stealth spread’ [9].  81 
The fact that specialist readers know these nuances does not alter the fact that the loosely 82 
used ‘CRE’ and ‘CRO’ confuse as they percolate wider clinical and public health communities.  83 
 84 
‘Carbapenemase-producing’... Better than ‘carbapenem-resistant’ 85 
 ‘Carbapenemase-Producing Enterobacterales’ (CPE) and ‘Carbapenemase-Producing Organism’ (CPO) 86 
are more precise than ‘carbapenem-resistant’.  The only medically-important bacteria with strongly-87 
expressed, endogenous carbapenemases are Stenotrophomonas maltophilia and some 88 
Chryseobacterium and Aeromonas spp. [10]. Consequently all CPEs and almost all CPOs are 89 
exceptional, meriting concern. The counterpoint applies too: if a ‘CRE’ is resistant to only ertapenem 90 
and is not a CPE then imipenem and meropenem remain valid treatments at high dose.  Moreover, 91 
given the rarity of outbreaks involving such strains, infection control need not be enhanced above 92 
normal good practice.     93 
Asides from treatment issues, CPE/CPOs are important because (excepting SME and some 94 
IMI/NMC types) their enzymes typically are plasmid-mediated, facilitating horizontal spread. Some, 95 
notably K. pneumoniae ST258 with KPC enzymes, belong to globally successful strains (11-13) that, 96 
unlike porin mutants, unequivocally are biologically fit and able to cause outbreaks.   97 
 98 
Carbapenemase type is crucial 99 
A further step is needed, though, for it is unhelpful to lump different carbapenemases together.  The 100 
predominant KPC, OXA-48-like, Acinetobacter OXA (i.e. OXA-23, 24, 51 and -58) and metallo (i.e. IMP, 101 
VIM and NDM) enzymes differ greatly, leading to differing treatment implications [14]. Occasional 102 
isolates with FRI, GES, IMI and SME types add complexity, but are rare.  103 
If all carbapenemase types were evenly distributed authors would craft their language to 104 
specify the enzyme(s) meant.  But, in reality, carbapenemase distributions are regional or national, 105 
and the common CPE of an author may differ radically from those troubling his reader elsewhere.  KPC 106 
enzymes dominate in the Americas (except maybe Canada), Italy, Israel, Greece and Portugal, NDM in 107 
South Asia, and OXA-48-like in the Middle East (except Israel), North Africa, and much of Europe except 108 
for Italy, Greece and Portugal [15].   IMP and VIM MBLs dominate in carbapenemase-producing P. 109 
aeruginosa [16] except that SPM enzymes are prevalent in Brazil and that KPC types have spread in 110 
Colombia [11].  OXA-23 and -40 dominate everywhere in A. baumannii, with MBLs occasionally seen 111 
[17]. 112 
Again, examples illustrate how confusion spreads.  Lecturing internationally on carbapenem 113 
resistance one regularly took questions along the lines of “What do you think of double carbapenem 114 
combinations?”  Such combinations work on the principle that a high-affinity carbapenem acts as a 115 
competitive substrate/inhibitor, allowing the second carbapenem to exert its antibacterial activity. 116 
There is evidence of their efficacy against Enterobacterales with KPC enzymes [18] and the approach 117 
originated in the US [19] where these dominate [11].   Elsewhere in the world it is easy – reading 118 
(predominantly) US publications that used ‘carbapenemase’ and ‘KPC enzyme’ interchangeably – to 119 
miss the point that such combinations have little logic (or synergy) in countries where other 120 
carbapenemase types dominate.  121 
Knowing the carbapenemase family supports treatment choices.  Among older agents, (i) 122 
temocillin may be active against CPE with KPC enzymes, though MICs are often around a tentative 8 123 
mg/L breakpoint and clinical data are scanty [20], whilst (ii) ceftazidime typically retains activity 124 
against CPE with OXA-48-like enzymes if these lack ESBL or AmpC activity [21] and (iii) aztreonam 125 
remains active against those with either OXA-48 or MBLs if they lack ESBL or AmpC activity [22].    126 
More critically, knowledge of the carbapenemase type is vital to predicting the utility of 127 
recently licensed b-lactamase inhibitor combinations (Table 1). Ceftazidime/avibactam, 128 
meropenem/vaborbactam and imipenem/relebactam cover Enterobacterales with KPC 129 
carbapenemases in vitro. For meropenem/vaborbactam and ceftazidime/avibactam, there is trial or 130 
case-series evidence of superiority over colistin combinations [23,24]. Ceftazidime/avibactam 131 
additionally covers CPE with OXA-48-like carbapenemases (primarily because avibactam inhibits co-132 
produced ESBLs; OXA-48 lacks activity against ceftazidime) and, again, case series point to better 133 
outcomes than for colistin or carbapenem-based regimens [25].  Aztreonam/avibactam should 134 
additionally cover Enterobacterales with MBLs, again because avibactam should inactivate co-135 
produced ESBLs [22].    136 
None of these combinations has reliable activity against carbapenemase-producing P. 137 
aeruginosa, which mostly have MBLs and sufficient efflux to compromise aztreonam, or against OXA-138 
carbapenemase-producing A. baumannii.  Cefiderocol, (assuming a 4 mg/L breakpoint), potentially 139 
achieves wider activity, encompassing carbapenemase-producing P. aeruginosa and A. baumannii as 140 
well as most CPE.  Caveats are that its MICs show wide scatter, probably reflecting factors besides 141 
carbapenemase type and that, irrespective of species, MICs for isolates with NDM carbapenemases 142 
exceed those for isolates possessing other carbapenemase types.  (Public Health England, in 143 
preparation).  144 
Knowing the carbapenemase type is also pertinent for plazomicin. Most Enterobacterales with 145 
NDM enzymes co-produce ArmA or Rmt methyltransferases [26], altering the rRNA to prevent the 146 
binding of 3-ring aminoglycosides, including plazomicin.  Co-carriage of methyltransferases with other 147 
carbapenemases is rarer, but may be emerging for OXA-48-like enzymes [27]. K. pneumoniae ST258 148 
typically has an AAC(6’)-Ib acetyltransferase along with its KPC carbapenemase, thus compromising 149 
tobramycin and amikacin but not plazomicin or gentamicin [11]. 150 
 151 
Carbapenems against carbapenemase producers: again, type matters 152 
If newer agents are unavailable or inappropriate carbapenems are often added to regimens against 153 
CPE, particularly if their MICs remain low.  Justification comes e.g. from Vatopoulos et al., who found 154 
that carbapenems remained useful against bloodstream Klebsiella with VIM carbapenemases up to an 155 
MIC of 4 mg/L [28], whilst Tumbarello et al. found colistin combination regimens also including 156 
carbapenems were more efficacious than colistin monotherapy for bacteraemias due to K. 157 
pneumoniae with KPC carbapenemases [29], although a later trial suggest that this is the case only for 158 
severe infections [30]. 159 
However, a growing body of evidence, from animal models, small trials and case series 160 
suggests that the type of carbapenemase may be as important as the carbapenem MIC.  Fig. 1 depicts 161 
meropenem MICs for 906 CPE submitted to Public Health England (PHE) in 2015/16 [using data from 162 
ref 21], showing that values typically were lowest for isolates with OXA-48-like enzymes and highest 163 
for those with NDM types: 72.5% of isolates with OXA-48-like enzymes counted as ‘meropenem 164 
susceptible’ at EUCAST’s 2 mg/L clinical breakpoint and 56.7% at CLSI’s 1 mg/L value whereas 94.6% 165 
with NDM enzymes were resistant at EUCAST’s high breakpoint, with MICs >8 mg/L.   166 
Pharmacodynamics would therefore predict that carbapenems might remain widely useful against 167 
bacteria with OXA-48-like carbapenemases but not against those with NDM carbapenemases.  168 
Experience however suggests the opposite.  Wiskirchen et al. [31] found that acquisition of a blaOXA-48 169 
plasmid, conferring a doripenem MIC of 0.38 mg/L (versus 0.03 mg/L for the recipient and 170 
CLSI/EUCAST breakpoints of <1/>4 mg/L), dramatically reduced the efficacy of doripenem in a mouse 171 
thigh infection treated with a human-simulated regimen.  There was no such reduction of efficacy for 172 
ceftazidime, which had MICs of 0.25 mg/L irrespective of the plasmid.  Moreover, clinical outcomes 173 
with carbapenems against pathogens with OXA-48 enzymes are poor, even when MICs remain low:  174 
Cuzon et al. [32] recorded 3 deaths among 5 such cases, all with MICs of the therapeutically-used 175 
carbapenem within the EUCAST susceptible or (one case) intermediate/’susceptible increased dosage’ 176 
range.  Four patients, including two fatalities, also received colistin, to which all the bacteria were 177 
susceptible.   Larger studies reported 1-month mortality rates around 50% in bacteraemias due to CPE 178 
with OXA-48 carbapenemases, with many patients receiving carbapenems as well as colistin [33,34].  179 
Much better outcomes, with low mortality were reported when ceftazidime/avibactam was used in 180 
severely-ill patients infected by pathogens with OXA-48 enzymes [25]. In contrast to these poor 181 
outcomes against bacteria with the ‘weak’ OXA-48-like carbapenemases, Chibabhai et al. [35] noted 182 
good outcomes for carbapenems, alone or combined, in 18/26 cases infected by Enterobacterales 183 
with NDM enzymes, despite MICs mostly >8 mg/L.  This observation agrees with Wiskirchen et al. [36] 184 
who found humanised regimens of doripenem and ertapenem as effective against transconjugant K. 185 
pneumoniae with NDM-1 carbapenemase (MICs 4 and 16 mg/L, respectively) as against the plasmid-186 
free recipient (MICs 0.03 and 0.12 mg/L).  Neither carbapenem was effective against the 187 
corresponding transconjugant with a KPC carbapenemase despite a ‘doripenem-susceptible’ MIC of 1 188 
mg/L.    189 
Clearly the clinical studies are small and one cannot be certain that the animal studies will 190 
predict behaviour in humans; nonetheless, and taking these data collectively, there is a growing body 191 
of evidence to suggest that  OXA-48 enzymes cause more-problematic resistance in vivo than in vitro, 192 
whilst NDM types are less problematic in vivo than in vitro. Reasons remain uncertain, but a plausible 193 
contributory factor is that, in vivo, NDM-1 MBLs may struggle to acquire the zinc essential for their 194 
catalytic activity.  195 
 196 
Variation within carbapenemase families  197 
Identification of the carbapenemase family is as much as can be reasonably expected of diagnostic 198 
laboratories at present, given the PCR and immunochromatography methods available (see below).  199 
But the future may demand identification within families.   200 
Over 53 IMP, 46 VIM, 24 KPC 14 NDM, and 12 OXA-48-like carbapenemases are described.  201 
Much of the variation within families matters only insofar as it complicates the design of 202 
comprehensive PCR and immunochromatographic detection methods, necessitating repeated 203 
‘tweaking’ as new variants are added to the detection repertoire.   In a few cases, however, there is 204 
consequential variation.  The clearest example is that changes to KPC carbapenemase – most often an 205 
Asp179Tyr substitution in the omega loop – increase ceftazidimase activity, thereby conferring 206 
ceftazidime/avibactam resistance whilst impairing activity against carbapenems [37] Such changes – 207 
which do not compromise meropenem/vaborbactam or imipenem/relebactam – may be selected 208 
during ceftazidime/avibactam therapy, perhaps particularly when the dosage has been reduced to 209 
(over)-compensate for renal insufficiency [38].   Another possible example concerns the NDM family, 210 
where higher-numbered variants, which perhaps evolved more recently, have higher affinity for zinc 211 
than NDM-1, and a greater ability to confer resistance on zinc-deficient media [39].  If, as speculated 212 
above, NDM-1 is less effective in vivo because it struggles to acquire zinc, then this variation may be 213 
significant, though the necessary animal studies with different NDM variants remain to be done.   214 
In the near future it may become necessary to split ‘carbapenemase’ families into sub-groups, 215 
in the same way as we do e.g. for TEM b-lactamases.  Asides from adding another layer of complexity 216 
for microbiologists and infectious disease physicians this will present a challenge to rapid detection 217 
methods – a clinician will reasonably wish to know if the blaKPC gene (say) found by diagnostic PCR 218 
encodes a classical variant or one that evades ceftazidime/avibactam. 219 
 220 
Clarity needed in Prescribing Information 221 
Throughout this article we had underscored the need for clarity in writing of carbapenem resistance 222 
and carbapenemases.  Unfortunately this is not evident in package inserts.  For meropenem-223 
vaborbactam the FDA insert (accurately) states ‘… not active against bacteria that produce metallo-b-224 
lactamases or oxacillinases with carbapenemase activity’ [40] but then indicates general breakpoints 225 
of S <4, R >8 mg/L. These will lead to many isolates with OXA-48-like enzymes being categorised as 226 
susceptible (see fig. 1) despite the lack of clinical evidence and even though vaborbactam does not 227 
inhibit OXA-48-like enzymes.  For ceftazidime-avibactam the insert reads: “In a subset of Gram-228 
negative pathogens … genotypic testing identified certain ESBL groups (e.g., TEM-1, SHV-12, CTX-M-229 
15, OXA-48) and AmpC that were expected to be inhibited by avibactam ….”[41].    This is unfortunate 230 
wording, to say the least: neither OXA-48 nor TEM-1 is an ‘ESBL,’ and the activity of 231 
ceftazidime/avibactam against isolates with OXA-48 is due to ceftazidime being stable to this enzyme 232 
rather than to its inhibition by avibactam.  The EMA is clearer than the FDA on carbapenemase types 233 
but, for meropenem/vaborbactam, its Specification of Product Characteristics reads “Vaborbactam’s 234 
inhibitory spectrum includes class A carbapenemases (such as KPC) and Class C carbapenemases… not 235 
class D carbapenemases … or class B metallo-β-lactamases….”[42]. To the best of our knowledge no 236 
Class C carbapenemase has been described, and there is no evidence that vaborbactam potentiates 237 
meropenem against AmpC hyperproducers in general. 238 
Prescribing information sheets for new drugs need to be clearer regarding the carbapenemase 239 
types covered, for example by incorporating a simple standard table of (i) which b-lactamases 240 
compromise the b-lactam partner, (ii) which of these are inactivated by the inhibitor, (iii) whether 241 
particular species with the particular enzyme are likely to be susceptible, and (iv) whether clinical trials 242 
support efficacy against producers of the particular enzyme.   243 
 244 
Practical aspects for diagnostic laboratories 245 
There remains the practical issue of identifying carbapenemases in routine practice, both to manage 246 
cross-infection risk – greater for CPE than other CRE – and to inform use of new-b-lactamase inhibitor 247 
combinations.   248 
For Enterobacterales, insight can be gleaned from relative resistance to ertapenem versus 249 
imipenem and meropenem, with single ertapenem resistance often pointing to AmpC or ESBL activity 250 
combined with impermeability, rather than to carbapenemases, particularly if 251 
cephalosporin/clavulanate or cephalosporin/cloxacillin synergy is also seen.  Hydrolytic tests (e.g. 252 
acidimetric/Carba-NP tests or carbapenem inactivation methods) distinguish CPE from other CRE [43] 253 
but do not sufficiently discern the particular carbapenemase type to support precision medicine; 254 
moreover OXA-48-like enzymes can be hard to detect by these methods which must either (i) be 255 
supplemented with additional phenotypic data (e.g. imipenem/EDTA synergy tests, which predict 256 
MBLs and  tests for high-level temocillin resistance, which predicts OXA-48-like) (Table 2) or (ii) be 257 
supplanted with PCR or immunochromatographic methods, which are reviewed separately [44].   258 
P. aeruginosa resistant only to carbapenems can be assumed to have lost OprD and not to 259 
have a carbapenemase. When P. aeruginosa isolates are broadly resistant, including to carbapenems, 260 
it is necessary to discriminate whether they have carbapenemases or – as is more frequent – 261 
combinations of OprD loss and upregulation of efflux and/or AmpC b-lactamase.   MBLs are the 262 
commonest carbapenemases here and can be sought by carbapenem/EDTA or 263 
carbapenem/dipicolinic acid tests, though the former are prone to give false positive results, probably 264 
because EDTA-extractable divalent cations ordinarily stabilise the P. aeruginosa outer membrane [45].   265 
A simpler approach is to test ceftolozane/tazobactam, where high-level resistance (MIC >16 mg/L or 266 
growth up to a 30 µg disc) is a good predictor that an isolate has either a carbapenemase or an ESBL 267 
[46]; the one caveat is that the few P. aeruginosa with OXA-48 or GES carbapenemases will be missed, 268 
being susceptible to ceftolozane/tazobactam. In the case of A. baumannii, most carbapenem-resistant 269 
isolates have OXA carbapenemases or (rarely) MBLs:  these can be distinguished by imipenem/EDTA 270 
synergy tests, though these often give weak false positive results (4- to 8-fold MIC reduction) for 271 
isolates with OXA enzymes; strong positives, with >16-fold synergy, are the preserve of MBL producers 272 
(PHE Data on file). 273 
 274 
Conclusions 275 
For as long as carbapenem resistance was exceptionally rare it was acceptable to term ‘carbapenem 276 
resistant’ and ‘carbapenemase-producing’ bacteria as single entities.   The proliferation of diverse 277 
carbapenemases and the advent of new therapies mean that this is no longer adequate.    New drugs 278 
or combinations may be an answer to CPE in one country where (say) KPC carbapenemases dominate, 279 
but not in another, where OXA-48 or MBL types are the ‘typical’ CPE.  Authors, referees and editors 280 
all have roles in ensuring clarity, as do licensing agencies and international agencies. 281 
Not only in the literature, but also in routine practice it is increasingly important to detect 282 
carbapenemase production rather than ‘carbapenem resistance’ and – wherever possible -  to identify 283 
the enzyme family present.    And, last, in the common vernacular ‘carbapenemase-producing’ or ‘non-284 
carbapenemase-producing’ should be encouraged.  ‘Carbapenem resistance’ is no longer sufficiently 285 
precise to aid therapeutic optimisation or to correctly alert infection control teams.   286 
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Table 1 Spectra of new and anticipated b-lactams and b-lactamase inhibitor combinations, in relation 441 
to bacterial group and carbapenemase type. 442 
Drug and statusa Enterobacterales P. aeruginosa A. baumannii 
 KPC OXA-
48-like 
MBL MBL MBL OXA 
Diazabicyclooctane-based inhibitor combinations 
Ceftazidime/avibactam (L) ++ ++ - - - - 
Imipenem/relebactam (L) ++ - - - - - 
Aztreonam/avibactam (PIII) ++ ++ ++ +b - - 
Boronate-based inhibitor combinations 
Meropenem/vaborbactam (L) ++ - - - - - 
Single agents 
Cefiderocol (L) ++ ++ +(+)c ++ +(+)c ++ 
 443 
++, broadly active; +, weak activity; - not generally active 444 
a L, licensed by either or both FDA and EMA; R, under review by FDA and/or EMA; PIII, in phase III 445 
trials.  Earlier-stage agents are excluded 446 
b Aztreonam only has weak activity in general vs. P. aeruginosa. 447 
c MIC are raised for isolates with NDM MBLs, which are the commonest MBLs in Enterobacterales and 448 
A. baumannii, (though not in P. aeruginosa) 449 
 450 
  451 
Table 2.  Predicting carbapenemase types from interpretive reading of phenotypes 452 





Resistant only to ertapenem among carbapenems, with strong 
cephalosporin/cloxacillin or cephalosporin/clavulanate synergy, 
predicting AmpC or ESBL activity respectively 
KPC • Strong potentiation of meropenem by vaborbactam 
• Meropenem resistance combined with susceptibility to temocillin 
OXA-48-like • High-level resistance to temocillin and piperacillin/tazobactam, 
coupled with carbapenem resistance or reduced susceptibility 
Metallo types (IMP, 
VIM, NDM) 
• Synergy between carbapenems and EDTA or dipicolinic acid 
combined with a lack of cephalosporin/clavulanate synergy and 
clear resistance to ceftazidime avibactam 
P. aeruginosa  
OprD loss, alone Resistance to carbapenems combined with susceptibility to all other b-
lactams 
OprD loss, combined 
with efflux or 
derepressed AmpC 
• Resistance that includes carbapenems and some or all penicillins 
and cephalosporins but with ceftolozane/tazobactam 
susceptibility retained (Can also arise with OXA-48, but extremely 
rare in species)  
Metallo types (IMP, 
VIM, NDM) 
• Strong carbapenem/EDTA synergy (>8-fold reduction in MIC), 
combined with clear resistance (MIC 16 mg/L) to 
ceftolozane/tazobactam and if ceftazidime MIC > aztreonam MIC. 
(NB weak carbapenem/EDTA synergy does not reliably indicate 
MBL production) 
Acinetobacter spp.  
OXA carbapenemase Carbapenem resistance with weak <8-fold carbapenem/EDTA 
synergy coupled to broad resistance to all other b-lactams 
Metallo types (IMP, 
VIM, NDM) 
Carbapenem resistance with strong >8-fold carbapenem/EDTA 




Note to Table 2. None of these behaviors is definitive, and interpretive reading should always be based 455 
on review of all susceptibility results.  For example the combination of resistance to meropenem, 456 
ceftazidime and cefepime together with clear susceptibility to aztreonam strongly suggests presence 457 
of an MBL in Enterobacterales, however most MBL-producing Enterobacterales fail to show this 458 
phenotype because they co-produce aztreonam-hydrolysing ESBLs. 459 
The table omits combinations of organism and enzyme that are extremely rare (P. aeruginosa with 460 
OXA-48-like carbapenemase) or localized (P. aeruginosa with KPC enzymes). 461 
 Unequivocal confirmation of carbapenemase type is best achieved by PCR or 462 
immunochromatographic methods.  463 
Fig 1 464 
 465 
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Fig 1 legend. 467 
MIC distributions of meropenem for Enterobacterales submitted to PHE’s Antimicrobial Resistance 468 
and Healthcare Associated Infection Reference Unit from July 2015 to July 2016. Methodology and 469 
collection as in references [21]. 470 
 471 
